1. 伊藤博崇、藤堂具紀:遺伝子治療各論:脳腫瘍。CLINICAL NEUROSCIENCE, 2020, 38(3), 359-364.
2. Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y, Todo T: Efficacy of a third-generation oncolytic herpes virus G47Δ in advanced stage models of human gastric cancer. Mol Ther Oncolytics, 2020, 17: 205-215. [DOI:10.1016/j.omto.2020.03.022]
3. Yamada T, Tateishi R, Iwai M, Koike K, Todo T: Neoadjuvant use of oncolytic herpes virus G47Δ enhances the antitumor efficacy of radiofrequency ablation. Mol Ther Oncolytics, 2020, 18: 535-545. [DOI:10.1016/j.omto.2020.08.010]
4. Oku M, Ishino R, Uchida S, Imataki O, Sugimoto N, Todo T, Kadowaki N: Oncolytic HSV-1 in combination with lenalidomide for plasma cell neoplasms. Br J Haematol, 2021 (published online Nov.20, 2020), 192: 343-353. [doi: 10.1111/bjh.17173]
5. Ishino R, Kawase Y, Kitawaki T, Sugimoto N, Oku M, Uchida S, Imataki O, Matsuoka A, Taoka T, Kawakami K, van Kuppevelt TH, Todo T, Takaori-Kondo A, Kadowaki N: Oncolytic virus therapy with HSV-1 for hematologic malignancies. Mol Ther, 2021 (published online Sep. 30, 2020), 29 (2): 762-774. [doi: 10.1016/j.ymthe.2020.09.041]
6. 伊藤博崇、藤堂具紀:悪性神経膠腫に対するウイルス療法。Medical Science Digest, 2020, 46 (8): 18-21.
7. 伊藤博崇、藤堂具紀:がん治療用ウイルス。Medical Science Digest, 2020, 46 (12): 9-12.
8. 奥山隆平、藤堂具紀:悪性黒色腫に対する最新ウイルス療法-T-hIL12の医師主導治験。Precision Medicine, 2020, 3 (12): 1-4.
9. Matsumura S, Nakamori M, Tsuji T, Kato T, Nakamura M, Ojima T, Fukuhara H, Ino Y, Todo T, Yamaue H: Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer. Oncotarget, 2021, 12(4): 344-354. [doi: 10.18632/oncotarget.27873]
10. Fukasawa K, Kadota T, Horie T, Tokumura K, Terada R, Kitaguchi Y, Park G, Ochiai S, Iwahashi S, Okayama Y, Hiraiwa M, Yamada T, Iezaki T, Kaneda K, Yamamoto M, Kitao T, Shirahase H, Hazawa M, Wong RW, Todo T, Hirao A, Hinoi E: CDK8 maintains stemness and tumorigenicity of glioma stem 1 cells by regulating the c-MYC pathway. Oncogene, 2021, 40(15): 2803-2815. [doi: 10.1038/s41388-021-01745-1]